Country for PR: United States
Contributor: PR Newswire New York
Monday, July 19 2021 - 11:43
AsiaNet
Bioelectronica Announces Hypercell(TM) Expansion for Antibody Discovery, Closing of Oversubscribed Series A Financing, Powering Local Hiring Growth and Expansion of Facilities in Reno
RENO, Nev., July 19, 2021 /PRNewswire-AsiaNet/ --

- Expansion of Hypercell(TM) for biopharma discovery with software. 

- Establishment of a second site increased lab capacity by over 45% and 
engineering capacity by over 70%.

Bioelectronica(R) Corporation ("Bioelectronica") announced today that it has 
secured an undisclosed amount in its Series A financing round due to increased 
interest in Hypercell(TM), a new hardware tool that can be used to discover new 
antibodies using computer vision, which are industrially and technologically 
timely and relevant. This is proven by Hypercell's recent win of an industry 
award at ISAC, a leader in flow cytometry. The judges and audience unanimously 
agreed that Bioelectronica's approach was the most innovative compared to its' 
peers.

Logo - https://mma.prnewswire.com/media/1447740/bioelectronica_Logo.jpg  

"One way to think of Hypercell(TM) and digital biology is as a video-game 
console, in which researchers can use software programming to develop new 
software-controlled workflows for biopharma applications like antibody 
discovery and other functional assays for biopharma applications" said Jonathan 
Hull, Co-Founder and CEO. "I personally like analogies with Nintendo(R) because 
I'm a Tetris fan, but that's subjective", said Hull. 

The funding has accelerated Bioelectronica's path and advanced plans to open a 
third research site in Nevada, effectively increasing the Company's laboratory 
space and engineering capacity by 45% and 70%, respectively. It also allowed 
the Company to continue to grow their team. Since January 2020, Bioelectronica 
has grown their team by 56%. The Company has been actively hiring top local 
talent in Reno, with 62% of all employees recruited from the University of 
Nevada, Reno. This milestone is a major move for Bioelectronica on its mission 
to develop Hypercell(R), a next-generation platform that uses patent-pending 
electrofluidic hardware, reagents and data science to expedite biopharma 
discovery and production workflows.

"As one of the fastest growing local biotech startups, we have been focused on 
hiring the best local talent," says Hull. "As we continue to grow our team, we 
increased our operational footprint with a new facility and are investing in 
employee growth and development to ensure that they are geared for success."

"It's been amazing seeing the growth trajectory of Bioelectronica," says 
Orlando Gonzalez, U.S. Army Captain (ret) and Advisor to Bioelectronica. "The 
company continues to sustain operational growth and has promoted an excellent 
team culture. This is evidenced by the Company's quarterly leadership 
development workshops, which have given me a true opportunity to engage with 
the team. This team has tremendous potential to take Bioelectronica to the next 
level." 

New hires include talent technical and commercial talent from Hamilton 
robotics, VWR and Europhins. Roger Chen, Founder and CTO, was previously at 
Roche and is a successful founder and entrepreneur. Hull commented, "I'm very 
proud of our team, and am optimistic about our reach into the research market 
in the coming years. Our culture is to train and promote from within, and it's 
already paying off. Our team is outstanding."

The company is exploring offices in Asia and Europe to keep pace with the 
fast-growing demand for research and new antibodies due to the pandemic. "While 
Reno has been a great place to incubate, we may need to consider new offices. 
We hope to soon begin work on new cell therapies, provided we can secure the 
growth-capital that we need to continue to expand at this pace" says Hull. 

About Bioelectronica 
Bioelectronica(R) is a research-stage biotechnology company building 
intelligent, digital tools for biopharama discovery, cell screening and cell 
sorting. Bioelectronica's platform technology combines computer vision, 
biochemical reagents and consumer electronics to enable unique 
software-controlled workflows. We believe that by transforming biochemistry 
through digital innovation, we fundamentally change the speed and price of 
therapeutics discovery and development. For more information on how your 
workflow can benefit from Bioelectronica's step change innovation, contact 
Jonathan Hull or the team at hello@bioelectronica.com. Bioelectronica(R) and 
Hypercell(R) are registered trademarks of Bioelectronica. Hypercell(R) is For 
Research Use Only.

Follow Bioelectronica at www.bioelectronica.com, on LinkedIn at 
www.linkedin.com/company/bioelectronica, and on Twitter @singlecellsort ( 
https://c212.net/c/link/?t=0&l=en&o=3231606-1&h=2316578601&u=https%3A%2F%2Ftwitter.com%2Fsinglecellsort&a=%40singlecellsort 
).

SOURCE  Bioelectronica
Translations

Japanese